Stay updated with breaking news from Nasdaq mltx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating)‘s stock had its “reiterates” rating reaffirmed by 22nd Century Group in a research report issued to clients and investors on Thursday, Benzinga reports. A number of other equities research analysts also recently commented on MLTX. Cantor Fitzgerald reiterated an “overweight” rating and issued a $23.00 price objective on shares […] ....
Guggenheim began coverage on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) in a report released on Monday morning, The Fly reports. The brokerage issued a buy rating on the stock. A number of other research analysts have also issued reports on MLTX. Wedbush assumed coverage on MoonLake Immunotherapeutics in a research report on Wednesday, […] ....
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) shares shot up 8.7% during trading on Thursday . The stock traded as high as $24.97 and last traded at $24.61. 497,425 shares traded hands during trading, an increase of 106% from the average session volume of 241,839 shares. The stock had previously closed at $22.65. Analysts Set New […] ....
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating)’s stock price fell 7.3% during trading on Tuesday . The stock traded as low as $21.46 and last traded at $22.12. 114,538 shares changed hands during mid-day trading, a decline of 50% from the average session volume of 227,863 shares. The stock had previously closed at $23.86. Wall Street […] ....
Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) were down 7.3% on Tuesday . The stock traded as low as $21.46 and last traded at $22.12. Approximately 114,538 shares changed hands during trading, a decline of 50% from the average daily volume of 227,863 shares. The stock had previously closed at $23.86. Analyst Ratings Changes […] ....